Denali Therapeutics Shares Are Trading Higher. The Stock May Be Moving on Continued Strength After Announcing on Thursday It Began Its Phase 2a Study of LRRK2 Inhibitor BIIB122 for LRRK2-associated Parkinson's Disease With Its First Participant Dosed.

BenzingaDec 6 13:03 ET

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Yahoo FinanceDec 6 11:31 ET

Express News | Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of Lrrk2 Inhibitor, Biib122, in Lrrk2-Associated Parkinson’s Disease

ReutersDec 5 08:00 ET

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

GlobeNewswireDec 5 08:00 ET

Denali Therapeutics Management to Meet With B. Riley

TipRanksDec 2 17:05 ET

B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $38

Moomoo NewsNov 28 13:31 ET · Ratings